Pathophysiological Mechanisms Involved in the Pronostic and Evolution of Non-Small Cell Lung Cancer (NSCLC) at All Stages of the Disease

This single-center observational cohort study conducted at Bordeaux University Hospital aims to establish a structured clinico-biological platform in non-small cell lung cancer (NSCLC) to investigate the biological mechanisms involved in tumor initiation, progression, and relapse across all disease stages (I-IV). A total of 150 consecutive adult patients with histologically or cytologically confirmed NSCLC will be included over a 3-year period. Tumor samples will undergo translational analyses. These biological data will be correlated with pseudonymized clinical data collected from medical records and the institutional clinical data warehouse. The primary objective is to characterize the molecular, metabolic, and immune mechanisms associated with tumor progression and recurrence in NSCLC. The central hypothesis is that integrating comprehensive clinical data with in-depth molecular and immunological analyses of tumor tissues will identify biologically distinct patterns associated with disease evolution, therapeutic resistance, and prognosis. Such integrated clinico-biological signatures may improve patient stratification and contribute to the identification of novel biomarkers and therapeutic targets in NSCLC.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

* Adult patients
* NSCLC treated at the Bordeaux University Hospital.
* TNM stage between I to IV
* Patient affiliated with or beneficiary of a social security scheme.
* Non opposition

Exclusion Criteria:

* Patients with small cell lung cancer.
* History of any other malignancy other than NSCLC within 1 years prior to screening. except for non-melanoma skin cancers, in situ cancers, or low-risk prostate cancer
* Pregnant or breastfeeding women.
* Patients with a medical or psychiatric condition or illness that compromises their ability to understand the information or participate in the study.
* Individuals subject to legal protection measures (legal guardianship, trusteeship or curatorship).
* Individuals deprived of their liberty by judicial or administrative decision.
* Individuals who are unable to give their consent.
* Patients who are in a period of exclusion following another study or who have participated in another interventional study involving a medicinal product within 30 days prior to entry into the protocol or who are participating in another clinical study.